PanGenomic Health Inc - Vancouver, Canada-based precision health company - Says subsidiary MUJN Diagnostics Inc has introduced its point-of-care Vitamin D test for the dental implant industry.

"We are very excited to expand our MUJN biomarker assessment platform beyond our initial focus of tracking precision medicine treatments for mental health conditions," says Vincent Lum, chief executive of MUJN Diagnostics & co-founder of PanGenomic Health.

"We believe there will be increasing demand from health practitioners in many fields for rapid point-of-care diagnostic tests of biomarkers to facilitate precision health. We believe the dental implant industry is a particularly promising market for our diagnostics platform, as there are over 500,000 dental implants placed annually in the US."

Current stock price: CAD0.025, down 17% on Wednesday

12-month change: down 88%

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.